Emerg Infect Dis. 2018 Jul;24(7):1188-1194. doi: 10.3201/eid2407.171928.
Antibodies are unique among biomarkers in their ability to identify persons with protective immunity to vaccine-preventable diseases and to measure past exposure to diverse pathogens. Most infectious disease surveillance maintains a single-disease focus, but broader testing of existing serologic surveys with multiplex antibody assays would create new opportunities for integrated surveillance. In this perspective, we highlight multiple areas for potential synergy where integrated surveillance could add more value to public health efforts than the current trend of independent disease monitoring through vertical programs. We describe innovations in laboratory and data science that should accelerate integration and identify remaining challenges with respect to specimen collection, testing, and analysis. Throughout, we illustrate how information generated through integrated surveillance platforms can create new opportunities to more quickly and precisely identify global health program gaps that range from undervaccination to emerging pathogens to multilayered health disparities that span diverse communicable diseases.
抗体在识别具有疫苗预防疾病保护免疫力的个体和测量对各种病原体的过去暴露方面具有独特的能力。大多数传染病监测都侧重于单一疾病，但使用多重抗体检测对现有血清学调查进行更广泛的测试将为综合监测创造新的机会。在这种观点下，我们强调了多个潜在协同领域，综合监测比通过垂直计划进行独立疾病监测的当前趋势更能为公共卫生工作增加价值。我们描述了实验室和数据科学方面的创新，这些创新应该会加速整合，并确定在标本采集、检测和分析方面的遗留挑战。自始至终，我们都说明通过综合监测平台生成的信息如何为更快速、更准确地识别全球卫生计划中的差距创造新的机会，这些差距范围从疫苗接种不足到新出现的病原体，再到跨越各种传染病的多层次健康差异。
